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Hofferberth et al Congenital Heart DiseaseAsymptomatic, primary prevention. Two patients
(patients 13 and 18) in this cohort underwent
VATS-LCSD as a prophylactic measure. The outcomes
were equivocal as to whether any real benefit was derived
from undergoing the procedure. With such limited experi-
ence and indeterminate results, our data do not support un-
dertaking prophylactic VATS-LCSD in all children
identified at high risk of fatal arrhythmias. Nevertheless,
there may be a subset of patients who possess a high-risk
genotype that would benefit from prophylactic LCSD treat-
ment. A recent study by Jons and colleagues21 demon-
strated that analysis of mutant-specific ion channel
characteristics in LQTS patients may be useful for clinical
risk stratification. Further investigation may reveal a spe-
cific genotype and phenotype that are associated with a
heightened risk profile and would, therefore, benefit from
adjunctive VATS-LCSD as a primary preventative strategy.
Nevertheless, we cannot recommend LCSD as a prophylac-
tic therapy.C
H
DCONCLUSIONS
In summary, we have documented that video-assisted
thoracoscopic LCSD can be safely and effectively per-
formed in most children and young adults with life-
threatening ventricular arrhythmias. This minimally
invasive procedure is a promising adjunctive therapeutic
option that achieves a beneficial response in most symptom-
atic patients. We advocate the use of this treatment in all
patients who remain symptomatic with recurrent life-
threatening arrhythmias, syncope, or frequent ICD
discharges, despite conventional medical therapy. This
treatment strategy should be considered as part of the treat-
ment armamentarium in all patients with recalcitrant
ventricular arrhythmias. The utility of LCSD as a prophy-
lactic therapy in high-risk pediatric patients must be further
elucidated before definitive recommendations can be made.References
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Dr Joseph Dearani (Rochester, Minn). Thank you, Dr Backer
and Dr Reddy.
Dr Hofferberth and colleagues have summarized their results of
a small series of 24 children with VATS sympathetic denervation
to treat life-threatening ventricular arrhythmias. Their technique
intentionally spares the entire left stellate ganglion. They demon-
strated a ‘‘marked reduction’’ of arrhythmias in 73% and elimina-
tion of arrhythmias in 55%. Two were lost to follow-up, and 2 had
1-month follow-up; this should be factored into the recurrence
equation.
Surgery was performed safely; however, I believe there are
shortcomings with this review. Most centers with the greatest
experience in treating these cardiac channelopathies intentionally
remove the lower half of the left stellate ganglion. The literature
has demonstrated that the optimal cardiac denervation includes
the removal of T4, T3, T2, and the lower pole of the left stellate
ganglion (T1). In fact, the greatest density of norepinephrine-con-
taining vesicles resides in the stellate ganglion (T1) and a portion
of T2. So, ideally, cardiac denervation would include a completerdiovascular Surgery c Volume 147, Number 1 409
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Dstellectomy. However, the upper pole of the left stellate ganglion is
preserved to minimize the potential risk of developing Horner
syndrome.
Among the largest programs that perform this specific left car-
diac sympathetic denervation operation (ie, taking the lower half
of the stellate ganglion and T2 through T4), there exceeds a 90%
reduction in arrhythmia burden that includes breakthrough faints
and breakthrough ICD shocks overall. Furthermore, the antifibril-
latory (ie, protective effect) of denervation therapy is disease and
disease genotype dependent, where it has been shown to be most
effective in LQT1 and CPVT, emphasizing the importance of gen-
otyping for all of these patients. For example, among the greater
than 30 LQT1 patients denervated in our practice, there have
been no breakthroughs to date with longer follow-up. Unfortu-
nately, we do not know the genotypes of the long QT patients in
this small series. If many or most were LQT1, then the higher
observed breakthrough rate further underscores the critical impor-
tance of including the lower pole of the left stellate ganglion in the
operation.
I believe cardiac denervation surgery for channelopathies
should not be viewed as a simple adaptation of minimally invasive
surgery performed for hyperhidrosis, and it probably should not be
performed at a pace of approximately one procedure per year.
Despite performing approximately 20 per year, we still encounter
pretty variable anatomic variation with the left stellate ganglion. In
addition, in our experience, we have now performed left cardiac
sympathetic denervation in over 110 patients with these potentially
life-threatening disorders. In the early part of our reported series,
there were 3 patients with eyelid ptosis. Importantly, to date, there
is no patient with a complete Horner (facial droop), in more than
110 patients.
In closing, I agree with your VATS approach to sympathectomy,
and I congratulate your team for performing it with low periproce-
dural morbidity. However, I respectfully disagree with your tech-
nique to intentionally spare the left stellate ganglion, leaving up
to a third of your patients with residual ventricular arrhythmias, re-
sulting in ICD discharges. This study demonstrates that this tech-
nique is less effective for this difficult problem, and I would
encourage you to acknowledge this higher incidence in arrhythmia
recurrence when the lower half of the stellate ganglion is
preserved.
Dr Hofferberth. Thank you very much for your comments,
Dr Dearani.
First, I would like to address the issue of the indications for
treatment in this study. The vast majority of the literature that ex-
ists using the VATS-LCSD procedure is in patients with cardiac
ion channelopathies, who are treated for secondary prevention.
Looking at our data, we had a 73% response rate among all-comers
with 2 patients in the series of 24 treated for primary prevention. If
you exclude those 2 patients out, that means that we have an 82%
response rate among the patients that were treated for secondary
prevention.
Published data from other centers that perform the
VATS-LCSD technique certainly show that an 82% response
rate is equivalent to the results attained across the entire global
experience to date. There was a review article published 2 years
ago out of Texas Children’s Hospital by Hwang and colleagues,
who reviewed all cases using VATS-LCSD procedure in children410 The Journal of Thoracic and Cardiovascular Surgwith congenital long QT syndrome. This article demonstrated
that, of the global experience, there was a 77% response rate,
defined in terms of arrhythmia reduction. The vast majority of
data available on this topic defines response to treatment as
reduced arrhythmia burden. As I alluded to in the presentation,
it is difficult to quantify arrhythmia burden; however, that is a lim-
itation across all of the studies in this area. Nevertheless, based on
the current criteria for treatment response, our results are equal to
the global experience.
Dr Dearani. There is an important difference between a 90%
to 95% success rate, with ICD discharges going off in children
with refractory ventricular arrhythmias compared to 55% to
70%. This is an evolving science. Genotyping has helped under-
stand expectations in abolishing arrhythmias substantially. We
have not had a single case of a permanent Horner syndrome
with facial droop in over 100 cases when the lower pole of the
stellate is removed. Life-threatening ventricular arrhythmia
recurrence, resulting in ICD discharge, is different than recur-
rence of atrial fibrillation. It is a truly life-threatening problem,
and striving for a 90% to 95% arrhythmia reduction rate without
causing complete Horner syndrome seems to be a better goal to
aim for.
It would be helpful for other surgeons in the audience to
comment. As we discussed earlier, general pediatric surgeons
and pediatric cardiac surgeons do this procedure. It is important
that the surgical community understand the differences and expec-
tations with the various sympathectomy techniques.
Dr Hofferberth. Thank you, Dr Dearani. Our institution does
not agree with the notion that removal of part or all of the left stel-
late ganglion is a morbidity-free approach. The most recent article
published out of the Mayo Clinic in 2012, which described their
experience performing VATS-LCSD with resection of the lower
half of the left stellate ganglion, demonstrates this is not a
morbidity-free approach, with just over 10% of patients devel-
oping a perioperative Horner syndrome.
There was also an article published last month by Schneider and
colleagues from a center in Munich, who reported their results per-
forming LCSD with resection of the lower half of the left stellate
ganglion in 10 patients with long QT syndrome. They reported that
7 of the 10 developed perioperative Horner syndrome. Our
approach has been to transect the sympathetic chain up, at the
base of the stellate ganglion, and in the process remove all of the
interior radiating nerve fibers, which is, as you state, the location
that releases the highest concentration of norepinephrine. By per-
forming the procedure in this fashion, we are effectively elimi-
nating the morbidity risks associated with this procedure without
sacrificing the treatment efficacy.
Dr James Tweddell (Milwaukee, Wis). Thank you. It was a nice
presentation. And although I would agree with Dr Dearani that this
is not a simple extension of a thoracoscopic sympathectomy for
hyperhidrosis, it is probably closer to that than the operations typi-
cally performed by most of the people in this room. So, when we
have encountered this problem, we have actually asked our adult
thoracic surgery colleagues to help us with this procedure. They
have tremendous experience with this. And, I think it is easier
for us to work with them as a team approach rather than try to rein-
vent the wheel on these patients; I did enjoy your presentation
much.ery c January 2014
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DDr Hofferberth. Thank you much for your comments,
Dr Tweddell.
Dr Laureano Molins (Barcelona, Spain). We have experience
with sympathectomy or better clipping for hyperhidrosis mainly.
We have little experience, 5 or 6 cases with babies. It is difficult
to decide if the stellate ganglion should be removed or not because
we do not want to have those Horner syndromes.
I think that the theory is to transect the lower part of the stellate
ganglion, but it is not easy to respect the whole one. So, in fact, I
have not done it, to resect the stellate ganglion, and the percentage
of the patients that went well was similar, 75% to 80%.
But, I would like first to congratulate you for your elegant pre-
sentation and to talk a little bit about bilateral approach. Could this
bilateral approach reach a high level of success? I really do not
know. And we begin always with left side, of course. We go
through until T6. But, I would like to know not only your experi-
ence but your opinion on that.
Dr Hofferberth. Thank you for your comments and question.
At this point in time, the experience of performing a bilateral sym-
pathectomy is limited at our center; however, the reason we did
include the comment on the conclusion slide is that most recent
patients treated with VATS-LCSD at our center had undergone a
left-sided sympathectomy and remained symptomatic. In this
particular case, we then decided to proceed with a second opera-
tion to perform a right-sided sympathectomy, and since that
time, that patient has been completely arrhythmia free. It is, obvi-
ously, a limited experience to date. However, this may be a strategy
that should be considered further in the future.
Dr Carl Backer (Chicago, Ill). I have 2 questions. The first re-
lates to a patient of ours with ventricular tachycardia treated by our
chief of anesthesia with a temporary sympathetic nerve block in
the left neck. This completely cleared up the arrhythmia and
then we electively took the patient for a thoracoscopic sympathec-
tomy several days later. Do you have any experience with tempo-
rary nerve blocks in the neck as a predictive study for this patient
population?The Journal of Thoracic and CaDr Hofferberth. As far as I am aware, there has not been any
experience using that as a temporary measure.
Dr Backer.Yes, and it worked, it was unbelievable, it was night
and day.
The second question I have relates to the fact that some of these
children are pretty small and putting in an epicardial ACID is not
without issues. Can we use sympathectomy as the primary ther-
apy? We had one patient in whom we did the thoracoscopic sym-
pathectomy, the arrhythmias went away, and we observed the
child for a long time. We are still discussing whether or not we
should put in an AICD. Do you have patients in whom you
have simply done the sympathectomy and then not proceeded
with an AICD?
Dr Hofferberth. There are certainly patients that have had a
sympathectomy with additional medical treatment and who did
receive an ICD. We view this procedure as an adjunctive ther-
apeutic strategy that should always be implemented in conjunc-
tion with established therapies. In patients treated with
VATS-LCSD for primary prevention, we would still treat
them with optimal medical therapy; however, there have been
some patients who have been spared from undergoing ICD
implantation.
Dr Backer. I failed to mention we did treat this patient medi-
cally, and we did watch in the hospital for over a week. I noticed
your mean hospital stay was 2 days. How long would you watch
a patient with a sympathectomy and medical therapy before you
would send them out?
Dr Hofferberth. We discharge all patients on medical therapy
and then proceed to have them followed up regularly with a cardi-
ologist. So, at this point, a patient that has received a sympathec-
tomy is always going to be on some form of antiarrhythmic
therapy.
Dr Backer. Thank you much. This really was an eye-opening
presentation. This was not even on my radar screen 10 years
ago, and certainly it has now become an effective therapy. Thank
you much.rdiovascular Surgery c Volume 147, Number 1 411
